Table 3 Baseline demographics and clinical characteristics of abatacept clinical trial patients and RA DMARD cohorts
| Â | Abatacept CDP (N = 4,134) | BC (N = 12,337) | NDB (N = 10,499) | PharMetrics (N = 52,444) | NOAR (N = 523) | Sweden ERA (N = 3,703) | Sweden Inpatient (N = 53,067) |
|---|---|---|---|---|---|---|---|
Age, n (%) | Â | Â | Â | Â | Â | Â | Â |
   18 to 44 | 1,015 (25) | 3,088 (25) | 1,442 (14) | 15,733 (30) | 109 (21) | 782 (21) | 4,776 (9) |
   45 to 74 | 2,988 (72) | 7,840 (64) | 7,586 (73) | 35,137 (67) | 366 (70) | 2,421 (66) | 29,718 (56) |
   ≥ 75 | 131 (3) | 1,409 (11) | 1,438 (14) | 1573 (3) | 48 (9) | 500 (14) | 18,573 (35) |
Female, n (%) | 3,323 (80) | 8,936 (72) | 7,971 (76) | 18,569 (76) | 357 (68) | 2,589 (70) | 37,678 (71) |
Duration of RA, n (%) | Â | Â | Â | Â | Â | Â | Â |
   <5 years | 1,353 (33) | 4,890 (40) | 2,726 (29)* | NA | 523 | 3,703 | NA |
   5 to 10 years | 1,192 (29) | 4,206 (34) | 1,902 (20)* | NA | 0 | 0 | NA |
   >10 years | 1,586 (38) | 3,241 (26) | 4,716 (50)* | NA | 0 | 0 | NA |
Concomitant medications, n (%)†|  |  |  |  |  |  |  |
   Oral corticosteroids | 2,657 (64) | 8,121 (66) | 4,588 (44) | 11,504 (48) | 194 (37) | NA | NA |
   NSAIDS | 3,113 (75) | 11,001(89) | 6,820 (65) | NA | 416 (80) | NA | NA |
Total follow-up (years) | Â | Â | Â | Â | Â | Â | Â |
   Mean | 2.1 | 4.9 | 3.3 | 2.2 | 7.9 | 3.6 | 5.6 |
   Median | 1.8 | 6.0 | 2.5 | 2.0 | 9.3 | NA | NA |